NEW YORK — The Australian drug maker CSL Ltd. said Monday that it will buy Novartis’s flu vaccine business for $275 million. CSL said the deal will make it the second-largest flu vaccine maker in the world. The Novartis business had $527 million in revenue in 2013.
Novartis’s vaccines business includes operations in Cambridge, Mass.
Novartis flu vaccines include Flucelvax, Fluvirin, and Fluad.
The Swiss company, which expects to ship about 60 million doses worldwide of its seasonal influenza vaccines for the 2014-2015 season, reported $57.92 billion in total revenue in 2013.